Efficacy analysis of ALK inhibitors for treating lung squamous carcinoma patients harboring ALK rearrangement. [PDF]
Wei J, Sun W, Zeng X, Zhou H, Song Z.
europepmc +1 more source
First-Line Alectinib vs. Brigatinib in Advanced Non-Small Cell Lung Cancer with ALK Rearrangement: Real-World Data. [PDF]
Jeon Y +6 more
europepmc +1 more source
ALK-rearranged renal cell carcinoma (ALK-RCC): A systematic review
Hong Li, Xiao-Hong Li
openaire +1 more source
Spotlight on the treatment of ALK-rearranged non-small-cell lung cancer. [PDF]
Jalal, Shadia I., Mamdani, Hirva
core +1 more source
A real-world retrospective study to assess efficacy and safety of alectinib as adjuvant therapy in IB-IIIB NSCLC patients harboring ALK rearrangement. [PDF]
Chang ZH +4 more
europepmc +1 more source
Combined small cell lung carcinoma harboring ALK rearrangement: A case report and literature review. [PDF]
Niitsu T +16 more
europepmc +1 more source
Concomitant EGFR mutation and ALK rearrangement in multifocal lung adenocarcinoma: a case report. [PDF]
Fan J +6 more
europepmc +1 more source
A case of primary pulmonary atypical carcinoid with EML4-ALK rearrangement. [PDF]
Liu N +7 more
europepmc +1 more source
Anaplastic lymphoma kinase (ALK) gene rearrangements
Yuranga Weerakkody +2 more
openaire +1 more source
Treatment beyond disease progression: ALK inhibitors in ALK-rearranged advanced NSCLC
N.B. Leighl +7 more
openaire +1 more source

